mRNA Expression and Genetic Polymorphisms Affecting DRD3 (rs6280) and HTR2A (rs6313) in Bruxism

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06457646

Enrollment

169

Registered

2024-06-13

Start date

2024-06-02

Completion date

2024-12-17

Last updated

2024-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bruxism

Keywords

Gene Expression, Bruxism, Sleep bruxism, Polymorphism, Genetic

Brief summary

The goal of this observational study is to learn about the genetic factors influencing bruxism, a condition characterized by teeth grinding, in a group of participants. The main questions it aims to answer are: * Is there a significant association between the rs6313 polymorphism of the HTR2A gene and bruxism? * Is there a significant association between the rs6280 polymorphism of the DRD3 gene and bruxism? Participants will: Provide DNA samples for genotyping of the DRD3 (rs6280) and HTR2A (rs6313) polymorphisms. Provide RNA samples to assess changes in the expression of HTR2A and DRD3. Researchers will compare the genetic data and RNA expression levels between individuals with bruxism and those without (controls) to see if there are significant genetic differences and expression changes associated with bruxism.

Interventions

GENETICGenetic polymorphism

The biological significance of HTR2A and DRD3 in bruxism remains unclear as molecular analyses, including genetic association studies, have not explored the mRNA expression of genes implicated in bruxism. This study aims to evaluate the influence of genetic polymorphisms affecting DRD3 (rs6280) and HTR2A (rs6313) on bruxism to identify potentially associated genotypes. Additionally, it aims to investigate the expression of HTR2A and DRD3 to elucidate their biological significance in bruxism.

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* be above 18 years of age and have a confirmed diagnosis of bruxism

Exclusion criteria

* Systemic diseases, * orofacial dysfunction, * acute symptoms such as neurodegenerative diseases (specifically Parkinsons disease), * Taking medication such as anxiolytics

Design outcomes

Primary

Measure	Time frame
PCR-RFLP Analysis	1 year

Contacts

Primary ContactYosra Gassara

chouchengassarayosra@gmail.com216-587-5455

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 5, 2026